- Home
- NPFD vs TBPH Comparison
NPFD vs TBPH Comparison
Compare NPFD & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPFD
- TBPH
- Stock Information
- Founded
- NPFD 2021
- TBPH 2013
- Country
- NPFD United States
- TBPH United States
- Employees
- NPFD N/A
- TBPH N/A
- Industry
- NPFD Trusts Except Educational Religious and Charitable
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- NPFD Finance
- TBPH Health Care
- Exchange
- NPFD Nasdaq
- TBPH Nasdaq
- Market Cap
- NPFD 456.7M
- TBPH 418.7M
- IPO Year
- NPFD N/A
- TBPH N/A
- Fundamental
- Price
- NPFD $18.86
- TBPH $9.61
- Analyst Decision
- NPFD
- TBPH Buy
- Analyst Count
- NPFD 0
- TBPH 4
- Target Price
- NPFD N/A
- TBPH $13.75
- AVG Volume (30 Days)
- NPFD 64.7K
- TBPH 200.9K
- Earning Date
- NPFD 01-01-0001
- TBPH 11-12-2024
- Dividend Yield
- NPFD 6.28%
- TBPH N/A
- EPS Growth
- NPFD N/A
- TBPH N/A
- EPS
- NPFD N/A
- TBPH N/A
- Revenue
- NPFD N/A
- TBPH $63,192,000.00
- Revenue This Year
- NPFD N/A
- TBPH $6.93
- Revenue Next Year
- NPFD N/A
- TBPH $45.31
- P/E Ratio
- NPFD N/A
- TBPH N/A
- Revenue Growth
- NPFD N/A
- TBPH 15.93
- 52 Week Low
- NPFD $14.50
- TBPH $7.44
- 52 Week High
- NPFD $18.07
- TBPH $11.71
- Technical
- Relative Strength Index (RSI)
- NPFD 48.56
- TBPH 62.56
- Support Level
- NPFD $18.35
- TBPH $9.38
- Resistance Level
- NPFD $19.30
- TBPH $10.10
- Average True Range (ATR)
- NPFD 0.26
- TBPH 0.33
- MACD
- NPFD -0.01
- TBPH 0.09
- Stochastic Oscillator
- NPFD 50.69
- TBPH 69.35
About NPFD Nuveen Variable Rate Preferred & Income Fund
Nuveen Variable Rate Preferred&Income is a newly organized, diversified, closed-end management investment company. The Fund's investment objective is to seek to provide a high level of current income and total return.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).